Replimune
@Replimune
Followers
693
Following
7
Media
89
Statuses
155
Igniting a systemic immune response to cancer. Our mission is to transform cancer treatment by pioneering novel oncolytic immunotherapies.
Woburn, MA & Oxford, UK
Joined December 2016
Earlier this week, data from the IGNYTE trial of RP1 combined with nivolumab in anti-PD-1 failed melanoma was published online in the Journal of Clinical Oncology #melanoma. Read the publication here:
ascopubs.org
PURPOSEEffective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is an HSV-1–based oncolytic immunotherapy, here evaluated in...
1
6
7
RT @CureMelanoma: The MRF Breakthrough Consortium (MRFBC) annual in-person meeting is officially underway at #ASCO2025! . This important ga….
0
1
0
This morning, we reported our fiscal fourth quarter and year end 2025 financial results, and provided an update on our progress. Read more here:
0
0
1
Today at #ESMO24 we presented data from the IGNYTE clinical trial of our investigational oncolytic immunotherapy RP1 combined with nivolumab in anti-PD-1-failed melanoma. Learn more about our late-breaking oral presentation here:
1
3
8
Today, we announced that the first patient has been randomized and dosed in the IGNYTE-3 study, our confirmatory Phase 3 trial of the investigational oncolytic immunotherapy, RP1 in combination with nivolumab in patients with advanced #melanoma. Read more:
0
1
7
In a new @BiotechTVHQ interview with @bradloncar, Replimune CEO Sushil Patel discusses our recent positive, topline data by independent central review of RP1 + nivolumab for anti-PD1 failed melanoma. Watch here:
biotechtv.com
Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from Iovance, and discusses Replimune's plans to file for acceler...
0
2
5
Today, we announced a $100M financing, which follows the strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma. Proceeds will enable full commercial scale up to support a potential launch in 2H 2025. Read more:
0
1
1
We had an amazing time at #ASCO24! We were honored to present the latest data demonstrating our clinical progress in oncolytic #immunotherapy across our portfolio. Missed our presentations? Our posters and data can be found at
0
1
3
Today, we shared topline primary analysis results by independent central review from our IGNYTE clinical trial of RP1 + nivolumab in anti-PD1 failed #melanoma. Read more:
0
3
7
Today at #ASCO24 we will present RP1 / IGNYTE data in anti-PD-1-failed melanoma and RP2 data in uveal melanoma. Learn more about these two oral presentations here:
0
0
3
While May is coming to an end, our work to improve the lives of patients living with #melanoma continues. This month – and every month – we recognize the individuals and their families who have been impacted by skin cancer.
0
0
1
Today, Replimune reported fiscal Q4 and year ended 2024 financial results and provided corporate updates:
0
0
0
Replimune was and continues to be built by amazing leaders and veterans in biotech – we are incredibly thankful for the contributions of our founders/executive team as we prepare for global growth and new milestones. Read more here:
0
0
2
Today, we announced changes to our executive leadership team designed to support preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma. Read more here:
0
0
3
RT @CureMelanoma: In just a few hours, we will join Dr. Gino from @uscnorris and patient Advocate, Donna Soskin for our Ask the Expert seri….
0
4
0
This morning, we shared a comprehensive update on RP1. The full announcement is available here:
0
0
3
Today, we present updated data on RP2 in uveal melanoma during a Plenary Session at the 20th International Congress of the Society for Melanoma Research. Read more on our website here:
1
2
4
Today, we shared updated interim results from the ARTACUS clinical trial. Read the release here:
1
1
5